Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
← catalyst calendarSponsored by Replimune, Inc. (industry) · REPL — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
231actual
Sites
56
Countries
Australia, Bulgaria, Canada +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-10-08 | actual | When the study began enrolling |
| Primary completion | Sep 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2019-08-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-01-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cutaneous Squamous Cell Carcinoma
- Advanced Cutaneous Squamous Cell Carcinoma
- Metastatic Cutaneous Squamous Cell Carcinoma
Interventions
- Drug: Cemiplimab — also filed as Libtayo
- Biological: RP1 — also filed as Genetically modified herpes simplex type 1 virus
Primary outcomes
what the primary-completion date above is the date OFObjective Response Rate (ORR) according to blinded independent review
measured up to 5 years
Complete Response Rate (CRR) according to blinded independent review
measured up to 5 years
Permalink · REPL's whole pipeline · Catalyst calendar · Every registered study · What changed